XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

Core Viewpoint - XORTX Therapeutics Inc. has entered into an extension agreement with Vectus Biosystems Limited to allow additional time for the acquisition of the Renal Anti-Fibrotic Therapeutic Program, with a new closing date set for March 31, 2026 [1][2] Group 1: Acquisition Details - The acquisition involves a novel chemical entity, VB4-P5, along with its associated intellectual property, regulatory documentation, and manufacturing data [1] - The original term sheet required the acquisition to close within 90 days of execution, but an amendment has extended this deadline [1] Group 2: Regulatory and Meeting Information - The acquisition is subject to the finalization of closing documentation, satisfaction of typical transaction conditions, and receipt of all regulatory approvals [2] - XORTX has scheduled its Annual and Special Meeting of Shareholders for March 24, 2026, with shareholders of record on February 20, 2026, entitled to vote [2] Group 3: Board Appointment - In connection with the appointment of Krysta Davies Foss to the board of directors, XORTX has granted 20,000 options to purchase common shares at an exercise price of CAD $0.69 for five years [3] Group 4: Industry Context - Chronic kidney disease (CKD) affects approximately 14% of adults globally, with around 35–37 million individuals in the United States [4] - Kidney fibrosis is a significant aspect of CKD progression, leading to organ dysfunction and high morbidity and mortality rates [5] - Current treatments for kidney fibrosis primarily focus on blood pressure control and dietary interventions, with no approved therapies specifically targeting or reversing kidney fibrosis [5] Group 5: VB4-P5 Program - Early preclinical data suggest that VB4-P5 has the potential to inhibit and possibly reverse kidney fibrosis [6] - The program has patent protection across more than 30 global jurisdictions, indicating broad development and commercialization opportunities [6] Group 6: Company Overview - XORTX is developing three clinically advanced products: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with respiratory virus infections [7] - The company is also working on XRx-225, a pre-clinical program for Type 2 diabetic nephropathy [7]